During a practice audit of patients over 75 years taking 10 or more regular medications, you identify several patients who would benefit from structured medication reviews. You are prioritising which patients to review first based on risk stratification. According to best practice guidance on medication reviews in primary care, which patient characteristic indicates HIGHEST priority for urgent structured medication review?
Q2
A 75-year-old man with COPD (post-bronchodilator FEV1 42% predicted), ischaemic heart disease, atrial fibrillation, and type 2 diabetes attends for medication review. He is on multiple inhalers: tiotropium, salmeterol/fluticasone 25/250 twice daily, and salbutamol as needed. Other medications include apixaban, bisoprolol, ramipril, atorvastatin, and metformin. He has had two exacerbations requiring oral steroids in the past year, the last one being 8 months ago. His current COPD symptoms are well-controlled with no exacerbations recently. Sputum cultures from his last exacerbation grew Pseudomonas aeruginosa. Which change to his inhaler therapy is MOST appropriate?
Q3
You are conducting a structured medication review for an 80-year-old man with heart failure (NYHA class II), type 2 diabetes, chronic kidney disease stage 3b (eGFR 38 ml/min/1.73m²), and benign prostatic hyperplasia. He lives alone and manages his medications independently using a dosette box filled by his daughter. He takes 13 different medications at various times throughout the day. He mentions he sometimes forgets his evening doses and finds the regimen 'complicated'. Which approach BEST addresses medication adherence in this context according to principles of medicines optimisation?
Q4
A 70-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and gastro-oesophageal reflux disease attends for review. She takes: methotrexate 15mg weekly, folic acid 5mg weekly (taken day after methotrexate), prednisolone 5mg daily, alendronic acid 70mg weekly, omeprazole 20mg daily, amlodipine 10mg daily, and calcium/vitamin D daily. Blood tests show: Hb 102 g/L (MCV 88 fL), WCC 3.8 × 10⁹/L, platelets 156 × 10⁹/L, ALT 68 U/L (previously 32), eGFR 58 ml/min/1.73m². Which aspect of her medication regimen requires MOST urgent attention?
Q5
A practice pharmacist is conducting a quality improvement project on anticholinergic burden in elderly patients with multimorbidity. She identifies a 73-year-old man taking 12 medications with a total Anticholinergic Cognitive Burden (ACB) score of 6. His medications include amitriptyline 50mg nocte for neuropathic pain, tolterodine 4mg for overactive bladder, lansoprazole 30mg, co-codamol 30/500, atorvastatin, ramipril, bisoprolol, aspirin, and metformin. He reports feeling 'foggy-headed' and has had two falls. Which intervention would have the GREATEST impact on reducing anticholinergic burden?
Chronic Disease Management UK Medical PG Practice Questions and MCQs
Question 1: During a practice audit of patients over 75 years taking 10 or more regular medications, you identify several patients who would benefit from structured medication reviews. You are prioritising which patients to review first based on risk stratification. According to best practice guidance on medication reviews in primary care, which patient characteristic indicates HIGHEST priority for urgent structured medication review?
A. A patient taking 15 medications who has been stable on the same regimen for 3 years with no recent adverse events
B. A patient recently discharged from hospital with five new medications added to their existing regimen (Correct Answer)
C. A patient taking multiple high-risk medications including warfarin, methotrexate, and lithium who attends regular monitoring
D. A patient who has reached the age of 75 and is now eligible for routine medication review under the Quality and Outcomes Framework
E. A patient with declining renal function (eGFR decreased from 68 to 54 over 12 months) taking eight regular medications
Explanation: ***A patient recently discharged from hospital with five new medications added to their existing regimen***
- **Hospital discharge** is a high-risk transition point where medication errors, **therapeutic duplication**, and communication gaps between primary and secondary care frequently occur.
- National guidelines (NICE and NHS England) prioritize patients with recent **regimen changes** for urgent review to ensure **medication reconciliation** and prevent adverse drug events.
*A patient taking 15 medications who has been stable on the same regimen for 3 years with no recent adverse events*
- While **polypharmacy** (taking 10+ medications) is a risk factor, clinical **stability** over three years suggests the regimen is currently tolerated and less urgent than an acute transition.
- This patient requires a review to reduce **pill burden**, but they do not meet the criteria for "highest priority" compared to a post-discharge patient.
*A patient taking multiple high-risk medications including warfarin, methotrexate, and lithium who attends regular monitoring*
- Patients on **narrow therapeutic index** drugs require careful supervision, but the fact they are attending **regular monitoring** indicates their risk is already being managed systematically.
- Urgent intervention is typically reserved for those with **unmonitored** high-risk drugs or those experiencing active complications.
*A patient who has reached the age of 75 and is now eligible for routine medication review under the Quality and Outcomes Framework*
- Routine eligibility based on age or **QOF requirements** is a preventative and administrative trigger rather than an urgent clinical risk stratification.
- This represents a **scheduled review** rather than an urgent need driven by clinical instability or a high-risk event like hospitalization.
*A patient with declining renal function (eGFR decreased from 68 to 54 over 12 months) taking eight regular medications*
- A gradual decline in **eGFR** over a year requires dose adjustments for renally cleared drugs, but the **12-month timeline** makes it less acute than a post-hospital change.
- This scenario necessitates a review to prevent **nephrotoxicity**, but it does not represent the immediate high-risk window associated with discharge reconciliation.
Question 2: A 75-year-old man with COPD (post-bronchodilator FEV1 42% predicted), ischaemic heart disease, atrial fibrillation, and type 2 diabetes attends for medication review. He is on multiple inhalers: tiotropium, salmeterol/fluticasone 25/250 twice daily, and salbutamol as needed. Other medications include apixaban, bisoprolol, ramipril, atorvastatin, and metformin. He has had two exacerbations requiring oral steroids in the past year, the last one being 8 months ago. His current COPD symptoms are well-controlled with no exacerbations recently. Sputum cultures from his last exacerbation grew Pseudomonas aeruginosa. Which change to his inhaler therapy is MOST appropriate?
A. Add a regular azithromycin prophylaxis regimen due to previous Pseudomonas infection
B. Switch from salmeterol/fluticasone to a triple therapy inhaler (LABA/LAMA/ICS combination) (Correct Answer)
C. Stop inhaled corticosteroids and continue bronchodilators only, given limited recent exacerbations
D. Reduce fluticasone dose to minimise steroid-related adverse effects including pneumonia risk
E. Add regular nebulised colistin for Pseudomonas suppression in COPD
Explanation: ***Switch from salmeterol/fluticasone to a triple therapy inhaler (LABA/LAMA/ICS combination)***- The patient is already on **triple therapy** (LAMA, LABA, ICS) using separate devices. Combining these into a single **LABA/LAMA/ICS** inhaler simplifies the regimen and improves **medication adherence**.- For patients with severe COPD (FEV1 42%) and frequent exacerbations (two in the past year), **triple therapy** is indicated to reduce exacerbation rates, and using a single device is preferred.*Add a regular azithromycin prophylaxis regimen due to previous Pseudomonas infection*- **Azithromycin prophylaxis** is typically considered for frequent exacerbators despite **optimal inhaled therapy**, often after ensuring the current inhaler regimen is maximally effective and simplified.- While the patient has a history of exacerbations, the initial step should be to optimize and streamline their primary inhaled maintenance therapy before adding prophylactic antibiotics, which carry risks of **antibiotic resistance** and side effects.*Stop inhaled corticosteroids and continue bronchodilators only, given limited recent exacerbations*- Stopping **inhaled corticosteroids (ICS)** is inappropriate in this patient due to a history of **frequent exacerbations** (two in the past year) and severe airflow limitation.- Discontinuing ICS in patients with a history of frequent exacerbations is associated with an increased risk of **future exacerbations** and worsening lung function.*Reduce fluticasone dose to minimise steroid-related adverse effects including pneumonia risk*- While **pneumonia risk** is a known concern with ICS, this patient's history of two exacerbations in the past year indicates a need for continued, effective anti-inflammatory therapy.- Reducing the **fluticasone dose** would be a step-down approach, which is not recommended for a patient who is a frequent exacerbator and has severe COPD.*Add regular nebulised colistin for Pseudomonas suppression in COPD*- **Nebulised colistin** is primarily used for chronic suppression of **Pseudomonas aeruginosa** in conditions like **bronchiectasis** or **cystic fibrosis**.- Its routine use for Pseudomonas suppression in COPD, especially without co-existing bronchiectasis, is not a standard recommendation in current guidelines and lacks strong evidence.
Question 3: You are conducting a structured medication review for an 80-year-old man with heart failure (NYHA class II), type 2 diabetes, chronic kidney disease stage 3b (eGFR 38 ml/min/1.73m²), and benign prostatic hyperplasia. He lives alone and manages his medications independently using a dosette box filled by his daughter. He takes 13 different medications at various times throughout the day. He mentions he sometimes forgets his evening doses and finds the regimen 'complicated'. Which approach BEST addresses medication adherence in this context according to principles of medicines optimisation?
A. Simplify the regimen by switching to once-daily preparations where possible and aligning administration times (Correct Answer)
B. Arrange for a district nurse to visit twice daily to supervise medication administration
C. Provide detailed written instructions about each medication and the importance of adherence
D. Reduce the total number of medications by stopping those not providing immediate symptom relief
E. Arrange urgent assessment of his cognitive function as non-adherence suggests early dementia
Explanation: ***Simplify the regimen by switching to once-daily preparations where possible and aligning administration times***- Medicines optimisation principles prioritise reducing **regimen complexity** and dosing frequency to improve **treatment adherence**, especially in elderly patients with polypharmacy.- Aligning schedules and using **once-daily formulations** addresses the patient's specific struggle with evening doses and his perception that the regimen is too 'complicated'.*Arrange for a district nurse to visit twice daily to supervise medication administration*- This is an overly restrictive and **paternalistic intervention** that undermines the patient's independence while he is still largely capable of self-care.- Resource-heavy interventions like **supervised administration** are typically reserved for patients with severe cognitive or physical impairments who cannot use aids independently.*Provide detailed written instructions about each medication and the importance of adherence*- While education is helpful, it does not solve the **structural complexity** of a 13-medication regimen with multiple dosing times throughout the day.- Information alone is often insufficient to overcome **unintentional non-adherence** caused by a burdensome and confusing schedule.*Reduce the total number of medications by stopping those not providing immediate symptom relief*- Arbitrarily stopping medications based only on immediate symptoms ignores **preventative treatments** (like those for CKD or heart failure) that reduce long-term morbidity.- While **deprescribing** is a key part of review, it must be based on a clinical risk-benefit analysis rather than simply the absence of immediate symptoms.*Arrange urgent assessment of his cognitive function as non-adherence suggests early dementia*- Forgetting parts of an exceptionally complex **13-medication regimen** is frequently a result of the system's burden rather than an indicator of **cognitive impairment**.- Formal cognitive assessment may be considered later, but the immediate priority should be the **optimisation** of a demonstrably difficult medication schedule.
Question 4: A 70-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and gastro-oesophageal reflux disease attends for review. She takes: methotrexate 15mg weekly, folic acid 5mg weekly (taken day after methotrexate), prednisolone 5mg daily, alendronic acid 70mg weekly, omeprazole 20mg daily, amlodipine 10mg daily, and calcium/vitamin D daily. Blood tests show: Hb 102 g/L (MCV 88 fL), WCC 3.8 × 10⁹/L, platelets 156 × 10⁹/L, ALT 68 U/L (previously 32), eGFR 58 ml/min/1.73m². Which aspect of her medication regimen requires MOST urgent attention?
A. The alendronic acid and omeprazole combination reducing bisphosphonate absorption
B. The low haemoglobin suggesting methotrexate-induced bone marrow suppression requiring urgent cessation
C. The elevated ALT indicating methotrexate hepatotoxicity requiring dose reduction or cessation (Correct Answer)
D. The combination of prednisolone and alendronic acid requiring additional osteoporosis monitoring
E. The declining renal function requiring methotrexate dose adjustment or alternative DMARD
Explanation: ***The elevated ALT indicating methotrexate hepatotoxicity requiring dose reduction or cessation***- The patient's **ALT** has doubled from baseline (32 to 68 U/L), which is a significant signal for **methotrexate hepatotoxicity** according to clinical monitoring guidelines.- Immediate action is required to withhold the medication and re-test **liver function** within 1-2 weeks to prevent progressive hepatic damage.*The alendronic acid and omeprazole combination reducing bisphosphonate absorption*- While some PPIs may theoretically affect mineral absorption, this combination is common and not an **urgent clinical concern** compared to organ toxicity.- The patient is already being treated for osteoporosis, and the **GORD** management is a higher symptomatic priority than minor absorption variances.*The low haemoglobin suggesting methotrexate-induced bone marrow suppression requiring urgent cessation*- The **Hb of 102 g/L** with a normal **MCV of 88 fL** (normocytic) often reflects **anaemia of chronic disease** in a patient with rheumatoid arthritis.- Although **bone marrow suppression** is a risk, the WCC and platelets remain within relatively safe ranges, making this less urgent than the liver function abnormalities.*The combination of prednisolone and alendronic acid requiring additional osteoporosis monitoring*- The patient is already appropriately prescribed **alendronic acid** and **calcium/vitamin D** to mitigate the bone loss risk associated with **prednisolone**.- While monitoring via **DEXA scans** is necessary in the long term, it does not constitute an "urgent" priority in the context of acute lab changes.*The declining renal function requiring methotrexate dose adjustment or alternative DMARD*- An **eGFR of 58 ml/min/1.73m²** indicates mild renal impairment but is still above the critical threshold (usually 30 ml/min) for absolute cessation.- While renal function affects **methotrexate clearance**, the current level does not require immediate discontinuation as urgently as the rising **ALT** levels do.
Question 5: A practice pharmacist is conducting a quality improvement project on anticholinergic burden in elderly patients with multimorbidity. She identifies a 73-year-old man taking 12 medications with a total Anticholinergic Cognitive Burden (ACB) score of 6. His medications include amitriptyline 50mg nocte for neuropathic pain, tolterodine 4mg for overactive bladder, lansoprazole 30mg, co-codamol 30/500, atorvastatin, ramipril, bisoprolol, aspirin, and metformin. He reports feeling 'foggy-headed' and has had two falls. Which intervention would have the GREATEST impact on reducing anticholinergic burden?
A. Switch tolterodine to mirabegron, a beta-3 agonist with no anticholinergic activity
B. Replace amitriptyline with duloxetine for neuropathic pain management
C. Stop lansoprazole as proton pump inhibitors contribute to cognitive impairment
D. Address both amitriptyline and tolterodine simultaneously by switching to alternatives (Correct Answer)
E. Reduce co-codamol dose as opioids can contribute to cognitive impairment
Explanation: ***Address both amitriptyline and tolterodine simultaneously by switching to alternatives***
- **Amitriptyline** and **tolterodine** are both high-burden drugs (ACB score of 3 each); replacing both is the most effective way to reduce the total **Anticholinergic Cognitive Burden (ACB)** score from 6 to near zero.
- Addressing both medications directly targets the patient's symptoms of **cognitive impairment ('foggy-headed')** and **falls**, which are classic adverse effects of high anticholinergic exposure in the elderly.
*Switch tolterodine to mirabegron, a beta-3 agonist with no anticholinergic activity*
- Switching **tolterodine** alone would only reduce the ACB score by 3, leaving the patient with a still-significant burden from the **amitriptyline**.
- While **mirabegron** is an excellent alternative for **overactive bladder** without anticholinergic effects, it does not address the neuropathic pain medication's contribution to the score.
*Replace amitriptyline with duloxetine for neuropathic pain management*
- Replacing **amitriptyline** with **duloxetine** (which has minimal to no anticholinergic activity) reduces the score by 3 but ignores the impact of **tolterodine**.
- Although this is a clinically sound step for **neuropathic pain**, a singular drug change is less impactful than a comprehensive review of all high-ACB agents.
*Stop lansoprazole as proton pump inhibitors contribute to cognitive impairment*
- **Lansoprazole** (a proton pump inhibitor) does not contribute to the **Anticholinergic Cognitive Burden** score, so stopping it would not improve the ACB metrics.
- While PPIs have other long-term risks, they are not the primary cause of **anticholinergic-mediated** delirium or falls in this scenario.
*Reduce co-codamol dose as opioids can contribute to cognitive impairment*
- **Co-codamol** (codeine/paracetamol) can cause sedation and falls due to its **opioid** component, but it does not carry a weight on the **ACB scale**.
- Reducing the dose may help general alertness but will not lower the **anticholinergic-specific** burden that this quality improvement project aims to address.
